• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 29, 2020
Company Drug/Device Medical Condition Status
Moderna mRNA-1273 coronavirus vials shipped to NIH for use in phase 1 trial
Magenta Therapeutics MGTA-145 stem cell mobilization needed completion of dosing in phase 1 trial
Pandion Therapeutics PT101 autoimmune diseases dosing of first subject in phase 1 trial
Actinium Pharmaceuticals Actimab-A 7+3 acute myeloid leukemia phase 1 trial dose escalation
Cyclo Therapeutics Trappsol Cyclo Niemann-Pick disease Type C Alzheimer’s disease patient enrollment completed for phase 1 trial
Abivax ABX196 inflammatory diseases, viral diseases and cancer dosing of first patient in phase 1/2 trial
BeiGene

SpringWorks

(Mapkure)
BGB-3245 advanced or refractory solid tumors initiation of phase 1 trial
Anokion KAN-101 celiac disease initiation of patient dosing in phase 1 trial
Neurimmune NI006 ATTR cardiomyopathy initiation of phase 1 trial
Inflazome Somalix harmful inflammation completion of phase 1 trial
Sojournix SJX-653 menopausal hot flashes initiation of phase 2 trial
Ascentage Pharma APG-1387 advanced pancreatic cancer approval of phase 1/2b trial
CytomX Therapeutics

Bristol-Myers Squibb
BMS-986249 alone and in combination with nivolumab selected advanced solid tumors initiated phase 2 expansion of phase 1/2a trial
Axcella AXA1665-002 complex diseases completed enrollment in phase 2 trial
Fulcrum Therapeutics losmapimod facioscapulohumeral muscular dystrophy completed patient enrollment in phase 2b trial
iTeos Therapeutics EOS-448 advanced cancers enrolled first patient in phase 1/2 trial
Antibe Therapeutics ATB-346 osteoarthritis pain last patient enrolled in phase 2b trial
Exelixis CABOMETYX (cabozantinib) radioactive iodine-refractory differentiated thyroid cancer phase 3 trial enrolling the first 100 of 300 patients at 150 sites globally
Marinus Pharmaceuticals oral ganaxolone CDKL5 Deficiency Disorder in children and young adults phase 3 trial initiated enrolling 100 patients
Gilead Sciences remdesivir COVID-19 two phase 3 trials initiated
PolyPid D-PLEX100 prevention of sternal wound infection after cardiac surgery phase 3 trial initiated enrolling first patient
Noxopharm Veyonda soft tissue sarcomas IND approved by the FDA
Translate Bio MRT5005 cystic fibrosis Fast-Track designation granted by the FDA
Debiopharm Debio 1143 confirmed diagnosis of previously untreated, unresectable locally advanced squamous cell carcinoma of the head and neck Breakthrough Therapy designation granted by the FDA
Lundbeck VYEPTI (eptinezumab-jjmr) migraine approved by the FDA
Eli Lilly Trulicity (dulaglutide) major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular (CV) disease or multiple cardiovascular risk factors new indication approved by the FDA
Seqirus FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted) seasonal influenza in individuals age 65 and older approved by the FDA
Teva Respiratory ArmonAir Digihaler (fluticasone propionate) Inhalation Powder) asthma approved by the FDA
Esperion Nexletol (bempedoic acid) adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C approved by the FDA
Esperion Nexlizet (bempedoic acid and ezetimibe) adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C approved by the FDA
Puma Biotechnology neratinib in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting supplemental NDA approved by the FDA
Acacia Pharma BARHEMSY (amisulpride injection) Postoperative Nausea and Vomiting approved by the FDA

 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing